Verona Pharma Plc ADR (NASDAQ: VRNA) closed the day trading at $16.73 down -0.54% from the previous closing price of $16.82. On the day, 714658 shares were traded.
Ratios:
For a better understanding of VRNA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 33.33 and its Current Ratio is at 33.33. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.20.
On August 26, 2022, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $31.Piper Sandler initiated its Overweight rating on August 26, 2022, with a $31 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 05 ’24 when Rickard Kathleen A. sold 36,248 shares for $2.22 per share. The transaction valued at 80,503 led to the insider holds 2,731,624 shares of the business.
Edwards Martin bought 33,736 shares of VRNA for $61,973 on Nov 20 ’23. The Director now owns 144,800 shares after completing the transaction at $1.84 per share. On Nov 06 ’23, another insider, EBSWORTH DAVID R, who serves as the Director of the company, bought 160,000 shares for $1.98 each. As a result, the insider paid 316,080 and bolstered with 844,643 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRNA now has a Market Capitalization of 1.35B and an Enterprise Value of 1.13B. Its current Enterprise Value per Revenue stands at 2.53k whereas that against EBITDA is -22.12.
Stock Price History:
Over the past 52 weeks, VRNA has reached a high of $23.81, while it has fallen to a 52-week low of $11.83. The 50-Day Moving Average of the stock is 17.93, while the 200-Day Moving Average is calculated to be 17.79.
Shares Statistics:
Over the past 3-months, VRNA traded about 596.11K shares per day on average, while over the past 10 days, VRNA traded about 473.08k shares per day. A total of 80.44M shares are outstanding, with a floating share count of 55.04M. Insiders hold about 31.57% of the company’s shares, while institutions hold 61.46% stake in the company. Shares short for VRNA as of Feb 15, 2024 were 6.84M with a Short Ratio of 11.23, compared to 6.79M on Jan 12, 2024.
Earnings Estimates
Current recommendations for the stock of the company come from 3 analysts. On average, analysts expect EPS of -$0.27 for the current quarter, with a high estimate of -$0.24 and a low estimate of -$0.3, while EPS last year was -$0.21. The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.17 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.12 and -$1.45 for the fiscal current year, implying an average EPS of -$1.27. EPS for the following year is -$0.51, with 3 analysts recommending between $0.48 and -$1.43.
Revenue Estimates
Based on 6 analysts’ estimates, the company’s revenue will be $149.38M in the next fiscal year. The high estimate is $210M and the low estimate is $100M. The average revenue growth estimate for next year is up 374.50% from the average revenue estimate for this year.
